{"effect":{"id":"dizziness","name":"Dizziness","severity":"mild","description":"Feeling lightheaded or unsteady. No clinical source on file states a cause for it.","clinicalRates":{"low":0.08,"medium":0.08,"high":0.08},"clinicalRatesNote":"A fixed reference table dated 2026-04-12, not derived from this corpus and carrying no per-effect citation of its own — see `sources` on ?q=effect&id=<id> for what was recorded behind each effect. It reaches published numbers two ways. (1) As the sole clinical base for an effect with no eligible corpus rate point — exactly the effects whose pooled corpus estimate is null (corpusClinical here, rateBase.clinical.pooledEstimate on the per-effect endpoint); the predictor marks these isFallback: true. (2) Since 2026-08-28, as a dose-tier rescale ratio applied to the corpus's OWN pooled rate wherever that tier's pooled clinical records are mostly dose-untagged; isFallback stays false in that case, and the predictor's clinical.basis states both endpoints and the dose-tag denominator while clinical.pooledPercentage carries the corpus rate before any adjustment. Full per-source detail: rateBase.clinical via ?q=effect&id=<id>. WITHDRAWN 2026-09-03 (decision literature-fallback-clinical-rate-2026-08-28, option c) for emotional_blunting only: this table had no rate-stating source at all for it, so its clinicalRate fields are null here and its predictor track carries `available: false` with no percentage — see clinicalRatesWithdrawn on ?q=effect&id=emotional_blunting. RE-SOURCED 2026-09-03 (same decision, option b) for fatigue only: its three tier values are one figure, 0.11, from the FDA Wegovy prescribing information revised 06/2026 (Table 3: fatigue incl. asthenia 11% on 2.4 mg, N=2,116, vs 5% placebo, N=1,261; URL in its sources) — the label reports no per-dose-tier rate, so no gradient is published for it, and it is a semaglutide figure applied at every dose tier regardless of molecule, as this whole table is. RE-SOURCED 2026-09-04 (decision pancreatitis-hairloss-dizziness-triple-derivation-2026-09-03) for hair_loss, dizziness and pancreatitis: their 2026-04-12 triples (1–3%, 2–5%, 0.5–1.2%) had no recorded derivation and their cited trial pages state no such figures; each is now one value at every tier from the same FDA Wegovy label — hair_loss 0.03 (Table 3: 3% on 2.4 mg, N=2,116, vs 1% placebo), dizziness 0.08 (Table 3: 8% vs 4%), and pancreatitis 0.002, which is NOT a proportion of patients like every other value in this table but the label's incidence RATE of 0.2 acute-pancreatitis cases per 100 patient-years of Wegovy exposure (4 adjudicated cases vs 1 on placebo, section 5) — read it with that unit. Figures served before 2026-09-04 for these three effects should not be cited.","confidenceNote":"`sourceDiversity` (formerly `confidence`, kept as a deprecated alias with the same value) measures SOURCE DIVERSITY, not precision: it is derived only from distinctSources (≤1 very_low, ≤3 low, ≤9 moderate, ≤24 high, ≥25 very_high) and is computed without reference to the confidence interval. It can read `moderate` on an estimate whose interval spans nearly the whole range — always read ciLowPct/ciHighPct alongside it, and treat a wide interval as the binding statement about how well we know the rate. The converse does NOT hold, and until 2026-09-11 nothing here said so: a NARROW interval is not evidence of a well-known rate. τ² (the between-study heterogeneity term) is 0 by construction when a single source entry contributes, so such an estimate publishes that one study's sampling interval and nothing else — read `intervalBasis` on every pooled block (`sampling_only_single_source` vs `sampling_plus_between_study`, with `intervalNote`/`intervalNoteNl` spelling it out) before reading a tight range as precision.","samplingNote":"Registry sampling bias, disclosed 2026-09-10 and corrected 2026-09-16: registry rows collected before 2026-09-10 through the rotation path were capped at the five highest-percentage arm rows per trial, which selects on the rate being measured (19 of the 25 trials with stored registry rows at the time; the six pinned pivotal trials — SURMOUNT-1, SELECT, STEP 1, STEP 2, SURPASS-CVOT, retatrutide phase 2 — were never affected). The collector was fixed 2026-09-10 and the 19 trials were re-collected in full between 2026-09-10 and 2026-09-16 (every tracked non-placebo arm row the registry posts is stored, verified against the live registry on 2026-09-16), so each study's entry in a pooled estimate is now the mean of every arm the registry posts for that term, not of its five highest. Method, per-trial measurements and the correction record: §4 Limitations and correction-log items 25 and 32 of the published methodology, https://github.com/saurabhgoyal75/magistra-predictor/blob/main/preprint/magistra-methodology.md.","modifiers":{"femaleFactor":1.15,"ageFactor65plus":1.5,"giHistoryFactor":1,"diabetesFactor":1.2,"firstMonthFactor":1.8},"modifiersNote":"Odds ratios hand-coded at the 2026-04-12 seed with no per-modifier citation recorded — treat each as an expert-coded prior, not a sourced estimate. The empirical estimator runs daily and 12 of the 15 tracked effects now clear its 10-eligible-point minimum, but zero empirical modifiers have been applied and none can be under the current extraction: all 1,111 eligible rate points behind those fits carry sex 'unspecified' and none carries an age band including 65 (measured 2026-09-18), so both fitted covariates are constant and every coefficient fits at 0. Model config is v5 (2026-09-12); its post-seed changes re-sourced four static base rates (v2, 2026-09-04) and aligned narrative fields with their sources (v3, v5). See ?q=help for the full methodology note.","reportingFrequency":{"mentions":2,"distinctReports":26,"sharePct":7.7,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."},"userReportedSeverity":"Users link it mostly to not drinking enough water or standing up too quickly. People on blood pressure medication should monitor closely as weight loss can lower BP further.","onsetDays":"Not stated by any clinical source on file.","durationWeeks":"Not stated by any clinical source on file.","managementTip":"Drink enough fluids and stand up slowly. If you take blood pressure medication, ask your doctor whether it needs reviewing.","sources":[{"name":"FDA Wegovy (semaglutide) prescribing information, revised 06/2026, Table 3: dizziness 8% on 2.4 mg (N=2,116) vs 4% placebo (N=1,261); Table 4 (7.2 mg trial): 1% / 5% / 6% for placebo / 2.4 mg / 7.2 mg","type":"clinical","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","weight":0.3},{"name":"Reddit r/Ozempic dizziness reports (2024-2026)","type":"user_report","weight":0.4},{"name":"PCOM Safety review (2025)","type":"news","url":"https://www.pcom.edu/south-georgia/news/safety-benefits-and-side-effects-of-glp-1-weight-loss-medications.html","weight":0.3}]},"dataPointCount":127,"rateBase":{"note":"Only externally citable, non-duplicated rates support an estimate. Shares of spontaneous adverse-event reports (FAERS) are reported separately — they are not incidence. A source marked rateKind: \"serious_ae\" states a rate from a trial registry's SERIOUS adverse-events table for a term posted in no other table of the same arm — a real stated figure, but a floor on all-cause incidence, since the registry lists non-serious events only above the trial's reporting threshold.","clinical":{"statedRates":97,"distinctSources":17,"sourceEntries":17,"pooledEstimate":{"ratePct":6.5,"ciLowPct":3,"ciHighPct":14,"statedRates":97,"distinctSources":17,"sourceEntries":17,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","intervalBasis":"sampling_plus_between_study","intervalNote":"","intervalNoteNl":"","confidence":"high","sourceDiversity":"high"},"confidenceNote":"`sourceDiversity` (formerly `confidence`, kept as a deprecated alias with the same value) measures SOURCE DIVERSITY, not precision: it is derived only from distinctSources (≤1 very_low, ≤3 low, ≤9 moderate, ≤24 high, ≥25 very_high) and is computed without reference to the confidence interval. It can read `moderate` on an estimate whose interval spans nearly the whole range — always read ciLowPct/ciHighPct alongside it, and treat a wide interval as the binding statement about how well we know the rate. The converse does NOT hold, and until 2026-09-11 nothing here said so: a NARROW interval is not evidence of a well-known rate. τ² (the between-study heterogeneity term) is 0 by construction when a single source entry contributes, so such an estimate publishes that one study's sampling interval and nothing else — read `intervalBasis` on every pooled block (`sampling_only_single_source` vs `sampling_plus_between_study`, with `intervalNote`/`intervalNoteNl` spelling it out) before reading a tight range as precision.","samplingNote":"Registry sampling bias, disclosed 2026-09-10 and corrected 2026-09-16: registry rows collected before 2026-09-10 through the rotation path were capped at the five highest-percentage arm rows per trial, which selects on the rate being measured (19 of the 25 trials with stored registry rows at the time; the six pinned pivotal trials — SURMOUNT-1, SELECT, STEP 1, STEP 2, SURPASS-CVOT, retatrutide phase 2 — were never affected). The collector was fixed 2026-09-10 and the 19 trials were re-collected in full between 2026-09-10 and 2026-09-16 (every tracked non-placebo arm row the registry posts is stored, verified against the live registry on 2026-09-16), so each study's entry in a pooled estimate is now the mean of every arm the registry posts for that term, not of its five highest. Method, per-trial measurements and the correction record: §4 Limitations and correction-log items 25 and 32 of the published methodology, https://github.com/saurabhgoyal75/magistra-predictor/blob/main/preprint/magistra-methodology.md.","seriousAeSources":0,"sources":[{"name":"ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With Obes — Dizziness","url":"https://clinicaltrials.gov/study/NCT04184622#adverse-events","rate":0.05,"sampleSize":636,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — STEP 1: Research Study Investigating How Well Semaglutide Wo — Dizziness","url":"https://clinicaltrials.gov/study/NCT03548935#adverse-events","rate":0.075,"sampleSize":1306,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) Compared With Dulaglutide — Dizziness","url":"https://clinicaltrials.gov/study/NCT04255433#adverse-events","rate":0.066,"sampleSize":6647,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of LY3437943 in Participants Who Have Obesity or Are — Dizziness","url":"https://clinicaltrials.gov/study/NCT04881760#adverse-events","rate":0.045,"sampleSize":69,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Drug-Drug Interaction (DDI) Study of Orforglipron With Car — Dizziness","url":"https://clinicaltrials.gov/study/NCT06370728#adverse-events","rate":0,"sampleSize":30,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness","url":"https://clinicaltrials.gov/study/NCT03929744#adverse-events","rate":0.027,"sampleSize":45,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Research Study to Compare a New Medicine Oral Semaglutide  — Dizziness","url":"https://clinicaltrials.gov/study/NCT04596631#adverse-events","rate":0.061,"sampleSize":66,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Dizziness","url":"https://clinicaltrials.gov/study/NCT05086445#adverse-events","rate":0.025,"sampleSize":18,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets T — Dizziness","url":"https://clinicaltrials.gov/study/NCT05132088#adverse-events","rate":0.06,"sampleSize":134,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Dizziness","url":"https://clinicaltrials.gov/study/NCT05548647#adverse-events","rate":0.042,"sampleSize":72,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of Orforglipron in Adult Participants With Obesity o — Dizziness","url":"https://clinicaltrials.gov/study/NCT05872620#adverse-events","rate":0.053,"sampleSize":331,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Research Study Looking at the Effect of Semaglutide on the — Dizziness","url":"https://clinicaltrials.gov/study/NCT05891496#adverse-events","rate":0.046,"sampleSize":22,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of Once-Daily Oral Orforglipron (LY3502970) in Japan — Dizziness","url":"https://clinicaltrials.gov/study/NCT05931380#adverse-events","rate":0.028,"sampleSize":61,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) in Adult Participants Wi — Dizziness","url":"https://clinicaltrials.gov/study/NCT05971940#adverse-events","rate":0.035,"sampleSize":143,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Long-term Safety Study of Orforglipron (LY3502970) in Part — Dizziness","url":"https://clinicaltrials.gov/study/NCT06010004#adverse-events","rate":0.03,"sampleSize":135,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Dizziness","url":"https://clinicaltrials.gov/study/NCT06440980#adverse-events","rate":0.022,"sampleSize":215,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — Research Study to Look at How Well Semaglutide is at Lowerin — Dizziness","url":"https://clinicaltrials.gov/study/NCT03611582#adverse-events","rate":0.128,"sampleSize":407,"rateKind":"incidence"}],"excluded":{"spontaneous_report_share":4,"seed_unverified":3,"no_rate":5},"usesPublishedFallback":false},"community":{"statedRates":0,"distinctSources":0,"sourceEntries":0,"excluded":{"seed_unverified":7,"no_rate":11},"usesPublishedFallback":true},"spontaneousReportShares":[{"source":"FDA FAERS — semaglutide — DIZZINESS","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"semaglutide\"","shareOfReports":0.029,"reports":2874},{"source":"FDA FAERS — liraglutide — DIZZINESS","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"liraglutide\"","shareOfReports":0.029,"reports":1517},{"source":"FDA FAERS — exenatide — DIZZINESS","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"exenatide\"","shareOfReports":0.028,"reports":2673},{"source":"FDA FAERS — orforglipron — DIZZINESS","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"orforglipron\"","shareOfReports":0.029,"reports":34}]},"dataPointsBySource":{"clinical":105,"regulatory":4,"user_report":13,"news":5},"sampleDataPoints":[{"sourceName":"FDA FAERS — semaglutide — DIZZINESS","sourceType":"regulatory","sourceUrl":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"semaglutide\"","extractedRate":0.029,"extractedSeverity":null,"extractedSampleSize":99460,"extractionConfidence":"high","scrapedAt":"2026-04-08T04:02:40.461Z"},{"sourceName":"FDA FAERS — liraglutide — DIZZINESS","sourceType":"regulatory","sourceUrl":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"liraglutide\"","extractedRate":0.029,"extractedSeverity":null,"extractedSampleSize":51432,"extractionConfidence":"high","scrapedAt":"2026-04-12T10:18:48.313Z"},{"sourceName":"FDA FAERS — exenatide — DIZZINESS","sourceType":"regulatory","sourceUrl":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"exenatide\"","extractedRate":0.028,"extractedSeverity":null,"extractedSampleSize":94688,"extractionConfidence":"high","scrapedAt":"2026-04-12T10:19:02.451Z"},{"sourceName":"STEP-2 Trial (Davies et al., Lancet 2021)","sourceType":"clinical","sourceUrl":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/fulltext","extractedRate":0.02,"extractedSeverity":"mild","extractedSampleSize":200,"extractionConfidence":"high","scrapedAt":"2026-04-12T12:37:28.021Z"},{"sourceName":"STEP-2 Trial (Davies et al., Lancet 2021)","sourceType":"clinical","sourceUrl":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/fulltext","extractedRate":0.03,"extractedSeverity":"mild","extractedSampleSize":500,"extractionConfidence":"high","scrapedAt":"2026-04-12T12:37:28.021Z"}],"lastUpdated":"2026-09-18"}